First-in-Class Lupus Drug Aces Phase III Test

Data at EULAR back Biogen, UCB's first-in-class lupus drug

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

First-in-Class Lupus Drug Aces Phase III Test

(MedPage Today) -- BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according to phase III trial data...

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals…

#Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improv...

Breakthrough Developments in Lupus and Kidney Transplant Treatments: Dapirolizumab Pegol and Felzartamab Lead the Way In recent pivotal advancements within the field of immunology, Biogen Inc. (NASDAQ: BIIB) and UCB (Euronext Brussels: UCB) have demonstrated significant progress in the treatment of challenging conditions such as systemic lupus erythematosus (SLE) and antibody-mediated rejection (AMR) in kidney transplant patients. These advancem…